The prevalence of microalbuminuria and ECG left ventricular hypertrophy in hypertensive patients in private practices in South Africa

Cardiovascular Journal of South Africa

Volumn 17, Issue 5, 2006, Pages 245-249

  Rayner, Brian ^a   Becker, Piet ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BODY HEIGHT; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; ECG ABNORMALITY; ETHNICITY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIVATE PRACTICE; SOUTH AFRICA; WAIST CIRCUMFERENCE;

ADULT; ALBUMINURIA; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREVALENCE; PRIVATE PRACTICE; SOUTH AFRICA;

EID: 33846141145     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Leeder S, Raymond S, Greenberg H. Cardiovascular Disease and Global Health: Threat and Opportunity. Health Aff (Millwood) 2005 [http://content. healthaffairs.org/cgi/content/abstract/hlthaff.w5.31v1].
2. Bradshaw D, Groenewald P, Laubscher R, et al. Initial burden of disease for South Africa, 2000. S Afr Med J 2003; 93: 682-688.
3. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758.
4. US Renal Data System. USRDS 1999 annual data report. Bethesda MD: National Institute of Diabetes and Digestive and Kidney Disease 1999.
5. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583.
6. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in US adults. Arch Int Med 2004; 140: 167-174.
7. Gerstein HC, Mann JFE, Zinman, B, et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286: 421-426.
8. Klausen KP, Shading H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects. Association with incident coronary heart disease and death. Hypertension 2005; 46: 33-37.
9. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14(S5): S1-85.
10. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
11. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
12. FJ Milne and VJ Pinkney-Atkinson for the Southern African Hypertension Society Hypertension Guideline Working Groups 2000 and 2003. Hypertension Guideline 2003 Update. S Afr Med J 2004; 94: 209-226.
13. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: The Cinderella of cardiovascular risk profile. J Am Coll Card 2001; 38: 1782-1787.
14. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
15. Parving H, Ostervy R, Ritz E. Diabetic nephropathy. In: Brenner BM, Levine S, eds. The Kidney. Philadelphia: Saunders, 2000: 1731.
16. Dahlöf B, Burke TA, Krobot K, et al. Population impact of losartan use on stroke in the European Union (EU): Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Hum Hypertens 2004; 1-7.
17. Mayet J, Chapman N, Li CK, et al. Ethnic differences in the hypertensive heart and 24-hour blood pressure profile. Hypertension 1998; 31: 1190-1193.
18. Wachteil K, Palmieri V, Olsen MH, et al. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hyper-tensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention for Endpoint Reduction. Am Hearl J 2002: 143: 319-326.
19. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, on behalf of UKPDS Group. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
20. Brenner BM, Cooper ME, de Zeeuw D, et al, RENAAL study investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
21. Lewis EJ, Hunsicker LG, Clarke WR, et al, collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
22. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
23. Ruggenenti P, Fassi A, Ilieva AP, et al, Bergamo Néphrologie Diabetes Complications Trial (BENEDICT) investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941-1951.